Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 11;5(2):e439.
doi: 10.1212/NXI.0000000000000439. eCollection 2018 Mar.

Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis

Andreas F Hottinger  1 , Rita de Micheli  1 , Vanessa Guido  1 , Alexandra Karampera  1 , Patric Hagmann  1 , Renaud Du Pasquier  1
Affiliations

Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis

Andreas F Hottinger et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab
A 71-year-old woman was diagnosed in 2014 with small-cell lung cancer. In 2016, she was treated with nivolumab and ipilimumab for systemic recurrence. Four days later, she developed severe disorientation and short-term memory deficits. Brain MRI shows bilateral contrast-enhancing lesions with associated T2 hyperintensity of the hippocampi (A and B). The images normalize after 6 months of treatment with natalizumab (C and D).
See this image and copyright information in PMC

References

    1. Williams TJ, Benavides DR, Patrice KA, et al. . Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933. - PubMed
    1. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806–812. - PubMed
    1. Cuzzubbo S, Javeri F, Tissier M, et al. . Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017;73:1–8. - PubMed
    1. Larkin J, Chmielowski B, Lao CD, et al. . Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017;22:709–718. - PMC - PubMed
    1. Royal RE, Levy C, Turner K, et al. . Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828–833. - PMC - PubMed